세계의 수면 보조 시장 규모는 2023년 818억 달러에서 2031년에 1,349억 7,000만 달러에 달할 것으로 예측되며, 2024-2031년의 예측 기간에 CAGR로 6.46%의 성장이 전망됩니다. 시장은 수면장애 환자의 증가, 수면장애에 관한 연구개발 활동의 증가, 숙면과 건강상 영향에 관한 의식의 향상 등의 영향을 받아 보다 빠른 페이스로 성장할 것으로 예측됩니다.
개인의 수면을 개선하고 불면증, 수면무호흡증, 하지불안증후군, 수면무호흡증과 같은 수면장애를 완화하는 제품을 수면 보조라고 합니다. 이 옵션에는 처방약, 처방전 없이 구입할 수 있는 보충제, 약초 요법, 수면 추적 장비 및 스마트 매트리스와 같은 새로운 기술이 포함됩니다. 최근 수년간 수면 보조에 대한 수요가 크게 증가하고 있습니다. 그 배경에는 건강과 웰빙의 필수 요소로서 수면의 필요성이 증가하고 있기 때문입니다. 스트레스 증가, 바쁜 생활 방식, 기술 기기의 보급 등도 수면을 방해하는 요인으로 작용하고 있습니다. 수면 부족이 건강에 미치는 악영향이 점점 더 분명해짐에 따라 이 문제를 해결하기 위해 자연 요법을 찾는 사람들이 점점 더 많아지고 있습니다. COVID-19 팬데믹으로 인해 많은 사람들이 불안감과 수면장애를 경험하면서 이러한 수요 증가에 더욱 박차를 가하고 있습니다. 이러한 상황으로 인해 고객들은 치료를 받으려 하고, 동시에 의료진에게 수면 보조를 권장해야 한다는 압력이 커지고 있습니다. 더 많은 사람들이 정신질환을 털어놓고, 제품의 기술 혁신이 발전하고, 정신건강 문제에 대한 관용이 증가함에 따라 수면 보조 시장은 계속 성장하고 있으며, 소비자 집단과 기업 모두에게 큰 관심을 불러일으키고 있습니다.
2023년 5월, 삶의 질을 향상시키는 의약품 혁신에 주력하는 바이오 제약 기업 Avadel Pharmaceuticals plc는 미국 식품의약국(FDA)이 LUMRYZ를 최종 승인했다고 발표했습니다. 성인 기면증 환자의 수면무호흡증 또는 주간과다졸림증(EDS) 치료를 위해 취침시 1회 복용하는 서방형 나트륨 옥시베이트 제제입니다. 이번 최종 승인으로 LUMRYZ는 기면증 환자를 위해 FDA가 승인한 최초이자 유일한 취침 전 1회 복용 옥시베이트 제제입니다. 또한 LUMRYZ는 FDA로부터 희귀질환 치료제로서 독점적 사용권을 부여 받았습니다.
세계의 수면 보조 시장에 대해 조사분석했으며, 시장 규모와 예측, 시장 역학, 주요 기업의 상황 등을 제공하고 있습니다.
Global sleep aids market is projected to witness a CAGR of 6.46% during the forecast period 2024-2031, growing from USD 81.80 billion in 2023 to USD 134.97 billion in 2031. The market for sleep aids is anticipated to grow at a faster pace under the influence of rising cases of sleep disorders, increased R&D initiatives around sleep disorders, and heightened awareness about sound sleep and its health implications.
Products that help individuals sleep better and mitigate sleep disorders, including insomnia, sleep apnea, and restless leg syndrome, are referred to as sleep aids. This option includes prescription medications, over-the-counter supplements, herbal remedies, and newer technologies such as a sleep-tracking device and smart mattresses. Sleep aids have experienced a highly increasing demand in recent years, heralded by the very awareness of the increasing need for sleep as an integral part of health and wellbeing. Increased stress levels, busy lifestyles, and widespread influences of technological gadgets have also contributed to disturbances in sleep. As the ill effects of sleep deprivation on health become more and more apparent, increasingly more individuals seek natural remedies to eliminate this issue. The pandemic has further fueled these rising needs, with many people experiencing heightened anxiety levels and disturbances in their sleep. These conditions made customers seek a cure, and at the same time, increased pressure on healthcare professionals to recommend sleep aids. As more and more people come forward to discuss mental disorders, product innovation, and increased tolerance toward mental health issues, the sleep aid market continues to gain momentum, thus bringing significant interest to both consumer groups and businesses.
In May 2023, Avadel Pharmaceuticals plc, a biopharmaceutical company focused on transforming medicines to improve lives, announced that the U.S. Food & Drug Administration (FDA) has granted final approval to LUMRYZ. LUMRYZ is an extended-release formulation of sodium oxybate intended to be taken once at bedtime for treating cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. With this final approval, LUMRYZ becomes the first and only FDA-approved once-at-bedtime oxybate for people living with narcolepsy. Additionally, LUMRYZ has been granted Orphan Drug Exclusivity by the FDA.
Rising Sleep Troubles Among People to Boost Market Demand
The growing incidence of sleeping disorders is generating high demand for sleep aids all over the world. There are several reasons for this. The elderly population is more prone to sleeping problems, and the related customer base is huge. Other factors for the increase of sleep disorders including modern lifestyle are stress levels, irregular work hours, and increased time in front of screens, which have disrupted normal sleep cycles in almost all the strata of the population. Public awareness of the need for sleep for overall health leads people to seek effective solutions further and thus increases market demand. Improving technology in sleeping aids, such as wearable devices and smart beds, also upgrades the product offerings and attracts consumers. According to the data of the National Council of Aging, around 39 million adults in the United States suffer from obstructive sleep apnea (OSA) and the number goes up to 936 million adults around the world who have mild to severe OSA. Snoring is a common symptom of sleep apnea in up to 94% of patients.
Growing Focus on R&D for Sleeping Aids to Bring Market Growth
The growth in R&D for sleep aids is expected to propel the market forward. As the issues relating to sleep, such as sleep apnea and insomnia, are increasing, there is a greater demand for a better solution. R&D initiatives have also led to the manufacturing of unique products, natural supplements, and sophisticated sleep technologies, catering to the diverse needs of the consumer. Companies, as well as startup firms, invest heavily in R&D, exploring various new compounds, formulations, as well as delivery methods, that can better improve the quality of sleep without adverse effects. Such products are validated through clinical trials and scientific studies, while consumer confidence generated by those studies boosts adoption. For instance, in July 2024, Corundum Neuroscience awarded a research grant to Tel Aviv University to develop a machine learning-based method for the non-invasive detection of abnormal brain activity in deep brain regions during sleep. The project aims to identify brain activity linked to dementia using high-density EEG. The goal is to create disease-specific biomarkers for neurodegenerative conditions and improve diagnostics and treatment.
Insomnia Segment to Dominate the Market
The insomnia market segment is expected to lead the sleep aid market, as sleeping disorders are on the rise and more people become aware of their health implications. The rising insomnia rates due to stress, anxiety, and lifestyle issues keep more people searching for a healthy solution that would provide them with better quality sleep. Such chronic insomnia affects a large portion of the population, and thus the demand for specialty products, such as prescription medications, over-the-counter supplements, or natural remedies is high. The emergence of new, insomnia-specific formulations and products is also on the rise, enhancing effectiveness and consumer acceptability. Strategic product launches for insomnia treatment further increase its market share, for instance, in July 2024, Jiangsu Simcere Pharmaceutical Co., Ltd. announced that the National Medical Products Administration has accepted the new drug application for Quviviq (daridorexant hydrochloride tablets), an innovative anti-insomnia drug developed in collaboration with Idorsia of Switzerland. Quviviq is a dual orexin receptor antagonist (DORA) and represents a new generation of anti-insomnia drugs. The drug has been approved for marketing in nine countries, including the United States, the United Kingdom, Switzerland, and Canada.
North America Dominates Sleep Aids Market
North America highly dominates the market for sleep aids. Several interrelated factors have placed the region at the top. The first reason is that North America, combined with lifestyle stressors, displays one of the highest rates of sleep disorders, especially insomnia and sleep apnea. Increased screen time and fast-paced work culture have led to this rising prevalence, increasing consumer awareness and demand for effective solutions to sleep issues. Advanced healthcare infrastructure and significant investments in research and development characterize North America as well. The majors, as well as startups, always are innovation and product launch leaders as they develop new sleep aids, prescription as well as over-the-counter formulations for consumers to avail. Culturally, it is pushing further the market with health and wellness awareness that more consumers are eager to find natural and holistic remedies besides pharmaceuticals.
Future Market Scenario (2024-2031F)
Smart mattresses equipped with AI integration are poised to drive significant growth in the sleep aids market. These innovative products utilize advanced sensors to monitor sleep patterns, heart rates, and breathing, providing real-time feedback and personalized sleep recommendations. By adjusting firmness, temperature, and support based on individual needs, smart mattresses enhance overall sleep quality. Furthermore, AI-driven insights can help users understand their sleep behavior, encouraging healthier habits. As consumers increasingly seek personalized and tech-driven solutions to improve sleep, the demand for smart mattresses is expected to rise, positioning them as key players in the evolving sleep aids market. In November 2023, DeRUCCI Group launched the T11 Pro Smart Mattress, the first AIoT smart mattress, designed to enhance sleep quality through advanced technology. It features 23 AI sensors that monitor various health metrics, including body temperature and heart rate, and 18 support airbags that adjust to users' movements. The mattress utilizes a patented algorithm for real-time adjustments tailored to individual sleeping positions, improving spinal health by over 40%. It connects with IoT devices for a fully integrated smart bedroom experience and offers features like snoring intervention and personalized sleep reports.
Key Players Landscape and Outlook
The sleep aid market features a dynamic landscape dominated by key players across pharmaceuticals, supplements, and technology sectors. Prominent pharmaceutical companies, such as Pfizer and Merck, offer prescription medications like Zolpidem and Eszopiclone, focusing on effectiveness and safety to address chronic insomnia. Over-the-counter brands like Unisom and Tylenol cater to consumers seeking immediate relief with accessible solutions. Recent activities in the sleep aids market include regulatory approvals and joint ventures for market expansion.
In March 2024, Vanda Pharmaceuticals Inc. announced that it received a Complete Response Letter (CRL) from the United States Food and Drug Administration (FDA) as part of its ongoing review of Vanda's supplemental New Drug Application (sNDA) for HETLIOZ (tasimelteon) in the treatment of insomnia characterized by difficulties with sleep initiation.
In October 2023, Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and other sleep disorders, announced a new joint venture with Shionogi & Co., Ltd., a leading global research-driven pharmaceutical company based in Japan. The joint venture, called Shionogi-Apnimed Sleep Science, LLC, will initially focus on accelerating the discovery, preclinical, and clinical development of novel pharmacologic solutions designed to address the complex pathology of OSA.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.